Platinum anticancer precision medicine

Bioplatinum Technologies LLC  develops platinum and metal-based precision medicine for anticancer and antiviral applications.  We exploit the inherent affinity of our compound library for sulfated glycosaminoglycans (GAGs) for drug discovery.

The Problem

  • Over 50% of all patients will receive a platinum drug, but development of resistance limits their utility.

  • Triplatin overcomes this resistance and combined with a diagnostic biomarker will allow for precision medicine across multiple cancers.

  • Triplatin underwent Phase I/II human clinical trials in the early 2000s – our new proprietary understanding of the mechanism of action is expected to increase the number and duration of responses to treatment. 

OVARIAN CANCER

  • 19,880 patients will be diagnosed this year in the US. Most patients are diagnosed with advanced disease. After initially successful surgery and chemotherapy, ovarian cancers recur and are drug resistant. Patients with advanced disease have a 30.8% chance of  surviving 5 years.

  • Some ovarian cancers are particularly insensitive to first-line chemotherapy.

PANCREATIC CANCER

  • 62,210 patients will be diagnosed this year in the US. Most patients are diagnosed with advanced disease that is inoperable. Patients with advanced disease have a 3.1% chance of surviving 5 years.

The Solution

  • The efficacy of platinum anti-cancer drugs is directly related to the amount of drug that enters the tumor.

  • Our research shows that tumors with high levels of sugars, called sulfated glycosaminoglycans (GAGs), are vulnerable to accumulation of Triplatin.

  • We propose that patient selection based on GAG expression will yield an increase in durable responses and present an advantage over currently used drugs.

  • We discovered that GAG-biomarkers, that were not available during the earlier clinical trials of Triplatin, predict sensitivity of patients to platinum drugs.

Triplatin overcomes resistance by precision targeting with sugars.

Tumors with high levels of sugars, called sulfated glycosaminoglycans (GAGs), are vulnerable to accumulation of Triplatin.

Antiviral Applications or Broad Spectrum Antivirals

The paucity of broad-spectrum antivirals is a major deficiency in preparedness for viral infectious disease emergencies. Current antiviral discovery is primarily aimed at finding specific treatments for individual viruses, and most antivirals block the function of one specific viral protein. Bioplatinum Technologies will develop a novel class of antivirals that target sulfated glycosaminoglycans (GAGs) on the cell surface to inhibit viral attachment and entry. Inhibitors that disrupt virion-GAG interactions are anticipated to have broad spectrum antiviral activity against a wide array of viral diseases, including those caused by coronaviruses, herpesviruses, adenoviruses, picornaviruses, monkey pox, Ebola, Dengue, and many others, that initiate infection by binding to GAGs.